Sunscreen ingredient
This article was originally published in The Rose Sheet
Executive Summary
BASF seeks 90-day extension to respond to FDA request for data on octyl triazone sunscreen; previous deadline was Oct. 9. BASF maintains it needs more time to compile recent effectiveness data and that extension would allow for a " more comprehensive and complete docket" on the substance. Beiersdorf submits letter to FDA Oct. 7 in support of BASF's time and extent application for ingredient, noting German firm has used octyl triazone in its own sun care products outside the U.S. for more than five years without "unusual adverse event experience." FDA requested data on the ingredient in a July 11 Federal Register notice (1"The Rose Sheet" July 14, 2003, Regulatory In Brief)...
You may also be interested in...
Regulatory In Brief
Wella buy gets green light: Federal Trade Commission grants regulatory approval to Procter & Gamble to proceed with its planned acquisition of German beauty firm Wella. P&G continues to pursue necessary regulatory and governmental approvals in other major markets including the EU, firm notes. P&G owns 79.17% of total registered share capital and about 84.9% of the value of outstanding shares of Wella following the close of the second and final tender period in June (1"The Rose Sheet" June 30, 2003, Finance In Brief)...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.